Comparing laser therapy and open surgery for temporal lobe epilepsy
Official title: Magnetic Resonance-guided Laser Interstitial Thermal Therapy for Mesial Temporal Lobe Epilepsy: A Prospective, Randomized, Open Blinded, End-point Trial
Run by Beijing Tiantan Hospital · NCT06720922 · Data updated 2026-11-12
This study is testing whether laser therapy works better than traditional surgery for people with drug-resistant temporal lobe epilepsy to see how well each option controls seizures.
Quick facts
| Study type | Interventional |
|---|---|
| Sex | All |
| Enrollment | 120 (estimated) |
| Sponsor | Beijing Tiantan Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Status | Recruiting |
| Started | July 21, 2025 |
| Main results expected | January 1, 2027 |
| Study ends | January 1, 2028 |
| Registry record updated | January 21, 2026 |
| Trial ID | NCT06720922 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are individuals with drug-resistant temporal lobe epilepsy who have been approved for surgical intervention.
✕Probably not a fit
Patients with significant medical comorbidities or a history of brain surgery may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study compares the clinical outcomes of magnetic resonance-guided laser interstitial thermal therapy (MRgLITT) with traditional open surgery for patients suffering from drug-resistant temporal lobe epilepsy (TLE). It aims to evaluate how these two interventions affect seizure control and overall prognosis. Additionally, the study will investigate various factors that may influence the success of seizure outcomes in these patients.
Why it matters
Potential benefit: If successful, this study could provide a less invasive treatment option for patients with temporal lobe epilepsy, potentially improving their quality of life.
How similar studies have gone: Other studies have shown promising results with MRgLITT in treating epilepsy, suggesting that this approach may be effective, though it is still considered a novel intervention compared to traditional methods.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * 18-65 years. * Drug-resistant mesial temporal lobe epilepsy. * Seizure frequency ≥ 1 time /month. * Participants approved. Exclusion Criteria: * History of brain surgery. * Intracranial space occupying lesions. * Individuals with significant medical comorbidities or conditions that pose an excessive risk for surgery, such as severe cardiovascular disease, respiratory disorders, or uncontrolled systemic infections.
Where it's running
-
Beijing Tiantan Hospital
Beijing, Beijing Municipality, China Recruiting
Study contacts
- Study coordinator: Kai Zhang, Dr.
- Email: zhangkai62035@sina.com
- Phone: 86 01059975051
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Overnight Temporal Interference Stimulation for Temporal Lobe Epilepsy
This study tests whether overnight, non-invasive temporal interference stimulation to the hippocampus can reduce seizure-related brain activity and improve sleep in adults with drug-resistant temporal lobe epilepsy.
-
Risk prediction for stroke and cognitive decline in Moyamoya disease and Moyamoya syndrome
A large multicenter study tests whether combining clinical data, imaging, lab and genetic information can predict who will have stroke or cognitive decline among people with Moyamoya.
-
Predicting unruptured brain aneurysm rupture risk with blood pressure variability and 3D changes
This study follows adults with unruptured intracranial aneurysms who are managed without surgery to see if blood pressure variability and 3D changes in the aneurysm can predict rupture risk using advanced AI.
-
Ischemic preconditioning to reduce ischemic events in Moyamoya with standard care
This study tests whether remote ischemic conditioning can lower stroke risk for adults with Moyamoya disease who are receiving standard medical care.
-
Rapid CSF ctDNA Test and Treatment Monitoring for Primary CNS Lymphoma
This study tests whether CSF circulating tumor DNA can quickly diagnose primary CNS lymphoma and monitor response to treatment in adults.
-
Biobank Registry for Primary CNS Lymphoma in China
This study will collect and register a long-term, multimodal biobank from adults with PCNSL to support future research, using patients with similar diagnoses as controls and healthy volunteers for comparison.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.